Extrawell Pharmaceutical Holdings Ltd

Extrawell maintains a strong liquidity position with a current ratio of 21.91, indicating a significant buffer of current assets over current liabilities. However, the company reported negative operating cash flow of -4.37 million HKD, which contrasts with its positive free cash flow of 228.63 million HKD. The company's return on equity of 16.68% and return on assets of 14.59% suggest strong profitability relative to its equity and asset base. The company's profitability metrics align with the preferred metrics for the Pharmaceuticals industry, which emphasize high returns on equity and assets. Extrawell's ROE and ROA exceed the typical thresholds for the sector, indicating efficient use of capital and strong operational performance. Extrawell's revenue is distributed across three segments: Manufacturing, Trading, and Gene Development. The Manufacturing segment is the primary source of self-produced products, including Transfer Factor Oral Solution and Wisk. The Trading segment focuses on imported pharmaceuticals such as Millibar and Skin Cap. The Gene Development segment is engaged in research and commercial development of gene-related technologies. The company's geographic exposure is not explicitly detailed in the input data, but the segments suggest a mix of domestic and international operations. The company's growth trajectory is supported by a positive free cash flow and a strong return on equity. However, the negative operating cash flow raises questions about the sustainability of its operations in the short term. The outlook for the current fiscal year and the next fiscal year is not explicitly provided, but the company's strong profitability and liquidity position suggest a positive direction. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.11 is low, suggesting minimal leverage. However, the negative net cash position after subtracting total debt is a key flag that warrants monitoring. The company has not disclosed any dilution sources in the input data, and the low dilution risk suggests that there is no immediate pressure for equity issuance. Recent events, including filings and transcripts, are not detailed in the input data. However, the company's strong financial performance and low debt levels suggest a stable and well-managed business. The absence of recent events does not necessarily indicate a lack of activity but may reflect the limited scope of the provided data.